Skip to main content
SpringerLink
Log in

Estrogen Receptor β and Breast Cancer

  • Chapter
  • First Online:
Estrogen Receptor and Breast Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Despite the primary role of estrogen receptor α (ERα) in mediating the effects of estrogen in malignant breast and as therapeutic target, the development of endocrine-resistant and metastatic phenotypes indicates the complexity of the mechanisms that regulate hormone signaling in the disease. The discovery of ERβ and its functional characterization has improved our understanding about the mechanism of estrogen receptor action, the regulation of estrogen signaling in breast tumors, and their response to therapy. The progressive decline of ERβ in pro-invasive lesions and invasive tumors points toward a role as suppressor of both tumorigenesis and progression in breast cancer. The antiproliferative and anti-invasive effects of the receptor and its agonists in preclinical models of breast cancer support these roles and delineate the mechanisms of action. The association of ERβ with clinical outcome proposes the potential use of the receptor as prognostic marker and its agonists in chemoprevention and therapeutic strategies for resistant and metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11(8):597–608. https://doi.org/10.1038/nrc3093

    Article  CAS  PubMed  Google Scholar 

  2. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA (2001) Mechanisms of estrogen action. Physiol Rev 81(4):1535–1565. https://doi.org/10.1152/physrev.2001.81.4.1535

    Article  CAS  PubMed  Google Scholar 

  3. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10):4831–4842. https://doi.org/10.1210/en.2006-0563

    Article  CAS  PubMed  Google Scholar 

  4. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481. https://doi.org/10.1200/JCO.1999.17.5.1474

    Article  CAS  PubMed  Google Scholar 

  5. Nelson AW, Groen AJ, Miller JL, Warren AY, Holmes KA, Tarulli GA, Tilley WD, Katzenellenbogen BS, Hawse JR, Gnanapragasam VJ, Carroll JS (2017) Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Mol Cell Endocrinol 440:138–150. https://doi.org/10.1016/j.mce.2016.11.016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Leygue E, Murphy LC (2013) A bi-faceted role of estrogen receptor beta in breast cancer. Endocr Relat Cancer 20(3):R127–R139. https://doi.org/10.1530/ERC-12-0389

    Article  CAS  PubMed  Google Scholar 

  7. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26(15):3505–3512

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Katzenellenbogen JA, Katzenellenbogen BS (1996) Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol 3(7):529–536

    Article  CAS  PubMed  Google Scholar 

  9. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M, Chambon P (1986) Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 24(1):77–83

    Article  CAS  PubMed  Google Scholar 

  10. Thomas C, Gustafsson JA (2015) Estrogen receptor mutations and functional consequences for breast cancer. Trends Endocrinol Metab 26(9):467–476. https://doi.org/10.1016/j.tem.2015.06.007

    Article  CAS  PubMed  Google Scholar 

  11. Leung YK, Gao Y, Lau KM, Zhang X, Ho SM (2006) ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia 8(4):242–249. https://doi.org/10.1593/neo.05853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci U S A 103(35):13162–13167. https://doi.org/10.1073/pnas.0605676103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Souza PCT, Textor LC, Melo DC, Nascimento AS, Skaf MS, Polikarpov I (2017) An alternative conformation of ERbeta bound to estradiol reveals H12 in a stable antagonist position. Sci Rep 7(1):3509. https://doi.org/10.1038/s41598-017-03774-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Grober OM, Mutarelli M, Giurato G, Ravo M, Cicatiello L, De Filippo MR, Ferraro L, Nassa G, Papa MF, Paris O, Tarallo R, Luo S, Schroth GP, Benes V, Weisz A (2011) Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics 12:36. https://doi.org/10.1186/1471-2164-12-36

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhao C, Gao H, Liu Y, Papoutsi Z, Jaffrey S, Gustafsson JA, Dahlman-Wright K (2010) Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Res 70(12):5174–5183. https://doi.org/10.1158/0008-5472.CAN-09-4407

    Article  CAS  PubMed  Google Scholar 

  16. Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS (2010) Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol 24(1):47–59. https://doi.org/10.1210/me.2009-0252

    Article  CAS  PubMed  Google Scholar 

  17. Le TP, Sun M, Luo X, Kraus WL, Greene GL (2013) Mapping ERbeta genomic binding sites reveals unique genomic features and identifies EBF1 as an ERbeta interactor. PLoS One 8(8):e71355. https://doi.org/10.1371/journal.pone.0071355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Williams C, Edvardsson K, Lewandowski SA, Strom A, Gustafsson JA (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27(7):1019–1032. https://doi.org/10.1038/sj.onc.1210712

    Article  CAS  PubMed  Google Scholar 

  19. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Banhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen YG, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronje MJ, Cuervo AM, Cullen JJ, Czaja MJ, D’Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Diaz-Araya G, Diaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farre JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fesus L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, Ghosh P, Giammarioli AM, Giatromanolaki AN, Gibson SB, Gilkerson RW, Ginger ML, Ginsberg HN, Golab J, Goligorsky MS, Golstein P, Gomez-Manzano C, Goncu E, Gongora C, Gonzalez CD, Gonzalez R, Gonzalez-Estevez C, Gonzalez-Polo RA, Gonzalez-Rey E, Gorbunov NV, Gorski S, Goruppi S, Gottlieb RA, Gozuacik D, Granato GE, Grant GD, Green KN, Gregorc A, Gros F, Grose C, Grunt TW, Gual P, Guan JL, Guan KL, Guichard SM, Gukovskaya AS, Gukovsky I, Gunst J, Gustafsson AB, Halayko AJ, Hale AN, Halonen SK, Hamasaki M, Han F, Han T, Hancock MK, Hansen M, Harada H, Harada M, Hardt SE, Harper JW, Harris AL, Harris J, Harris SD, Hashimoto M, Haspel JA, Hayashi S, Hazelhurst LA, He C, He YW, Hebert MJ, Heidenreich KA, Helfrich MH, Helgason GV, Henske EP, Herman B, Herman PK, Hetz C, Hilfiker S, Hill JA, Hocking LJ, Hofman P, Hofmann TG, Hohfeld J, Holyoake TL, Hong MH, Hood DA, Hotamisligil GS, Houwerzijl EJ, Hoyer-Hansen M, Hu B, Hu CA, Hu HM, Hua Y, Huang C, Huang J, Huang S, Huang WP, Huber TB, Huh WK, Hung TH, Hupp TR, Hur GM, Hurley JB, Hussain SN, Hussey PJ, Hwang JJ, Hwang S, Ichihara A, Ilkhanizadeh S, Inoki K, Into T, Iovane V, Iovanna JL, Ip NY, Isaka Y, Ishida H, Isidoro C, Isobe K, Iwasaki A, Izquierdo M, Izumi Y, Jaakkola PM, Jaattela M, Jackson GR, Jackson WT, Janji B, Jendrach M, Jeon JH, Jeung EB, Jiang H, Jiang JX, Jiang M, Jiang Q, Jiang X, Jimenez A, Jin M, Jin S, Joe CO, Johansen T, Johnson DE, Johnson GV, Jones NL, Joseph B, Joseph SK, Joubert AM, Juhasz G, Juillerat-Jeanneret L, Jung CH, Jung YK, Kaarniranta K, Kaasik A, Kabuta T, Kadowaki M, Kagedal K, Kamada Y, Kaminskyy VO, Kampinga HH, Kanamori H, Kang C, Kang KB, Kang KI, Kang R, Kang YA, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar A, Kerkhoff C, Kessel DH, Khalil H, Kiel JA, Kiger AA, Kihara A, Kim DR, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, Kitamoto K, Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BC, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Kouri Flores JB, Kovacs AL, Kraft C, Krainc D, Kramer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Kruger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, La Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, Laszlo L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, Le W, Le Cam L, Ledbetter DJ, Lee AJ, Lee BW, Lee GM, Lee J, Lee JH, Lee M, Lee MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, Lonial S, Loos B, Lopez-Berestein G, Lopez-Otin C, Lossi L, Lotze MT, Low P, Lu B, Lu Z, Luciano F, Lukacs NW, Lund AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MC, Malorni W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Marino G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin B, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, Meisler MH, Melendez A, Melia TJ, Melino G, Mena MA, Menendez JA, Menna-Barreto RF, Menon MB, Menzies FM, Mercer CA, Merighi A, Merry DE, Meschini S, Meyer CG, Meyer TF, Miao CY, Miao JY, Michels PA, Michiels C, Mijaljica D, Milojkovic A, Minucci S, Miracco C, Miranti CK, Mitroulis I, Miyazawa K, Mizushima N, Mograbi B, Mohseni S, Molero X, Mollereau B, Mollinedo F, Momoi T, Monastyrska I, Monick MM, Monteiro MJ, Moore MN, Mora R, Moreau K, Moreira PI, Moriyasu Y, Moscat J, Mostowy S, Mottram JC, Motyl T, Moussa CE, Muller S, Munger K, Munz C, Murphy LO, Murphy ME, Musaro A, Mysorekar I, Nagata E, Nagata K, Nahimana A, Nair U, Nakagawa T, Nakahira K, Nakano H, Nakatogawa H, Nanjundan M, Naqvi NI, Narendra DP, Narita M, Navarro M, Nawrocki ST, Nazarko TY, Nemchenko A, Netea MG, Neufeld TP, Ney PA, Nezis IP, Nguyen HP, Nie D, Nishino I, Nislow C, Nixon RA, Noda T, Noegel AA, Nogalska A, Noguchi S, Notterpek L, Novak I, Nozaki T, Nukina N, Nurnberger T, Nyfeler B, Obara K, Oberley TD, Oddo S, Ogawa M, Ohashi T, Okamoto K, Oleinick NL, Oliver FJ, Olsen LJ, Olsson S, Opota O, Osborne TF, Ostrander GK, Otsu K, Ou JH, Ouimet M, Overholtzer M, Ozpolat B, Paganetti P, Pagnini U, Pallet N, Palmer GE, Palumbo C, Pan T, Panaretakis T, Pandey UB, Papackova Z, Papassideri I, Paris I, Park J, Park OK, Parys JB, Parzych KR, Patschan S, Patterson C, Pattingre S, Pawelek JM, Peng J, Perlmutter DH, Perrotta I, Perry G, Pervaiz S, Peter M, Peters GJ, Petersen M, Petrovski G, Phang JM, Piacentini M, Pierre P, Pierrefite-Carle V, Pierron G, Pinkas-Kramarski R, Piras A, Piri N, Platanias LC, Poggeler S, Poirot M, Poletti A, Pous C, Pozuelo-Rubio M, Praetorius-Ibba M, Prasad A, Prescott M, Priault M, Produit-Zengaffinen N, Progulske-Fox A, Proikas-Cezanne T, Przedborski S, Przyklenk K, Puertollano R, Puyal J, Qian SB, Qin L, Qin ZH, Quaggin SE, Raben N, Rabinowich H, Rabkin SW, Rahman I, Rami A, Ramm G, Randall G, Randow F, Rao VA, Rathmell JC, Ravikumar B, Ray SK, Reed BH, Reed JC, Reggiori F, Regnier-Vigouroux A, Reichert AS, Reiners JJ Jr, Reiter RJ, Ren J, Revuelta JL, Rhodes CJ, Ritis K, Rizzo E, Robbins J, Roberge M, Roca H, Roccheri MC, Rocchi S, Rodemann HP, Rodriguez de Cordoba S, Rohrer B, Roninson IB, Rosen K, Rost-Roszkowska MM, Rouis M, Rouschop KM, Rovetta F, Rubin BP, Rubinsztein DC, Ruckdeschel K, Rucker EB 3rd, Rudich A, Rudolf E, Ruiz-Opazo N, Russo R, Rusten TE, Ryan KM, Ryter SW, Sabatini DM, Sadoshima J, Saha T, Saitoh T, Sakagami H, Sakai Y, Salekdeh GH, Salomoni P, Salvaterra PM, Salvesen G, Salvioli R, Sanchez AM, Sanchez-Alcazar JA, Sanchez-Prieto R, Sandri M, Sankar U, Sansanwal P, Santambrogio L, Saran S, Sarkar S, Sarwal M, Sasakawa C, Sasnauskiene A, Sass M, Sato K, Sato M, Schapira AH, Scharl M, Schatzl HM, Scheper W, Schiaffino S, Schneider C, Schneider ME, Schneider-Stock R, Schoenlein PV, Schorderet DF, Schuller C, Schwartz GK, Scorrano L, Sealy L, Seglen PO, Segura-Aguilar J, Seiliez I, Seleverstov O, Sell C, Seo JB, Separovic D, Setaluri V, Setoguchi T, Settembre C, Shacka JJ, Shanmugam M, Shapiro IM, Shaulian E, Shaw RJ, Shelhamer JH, Shen HM, Shen WC, Sheng ZH, Shi Y, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shintani T, Shirihai OS, Shore GC, Sibirny AA, Sidhu SB, Sikorska B, Silva-Zacarin EC, Simmons A, Simon AK, Simon HU, Simone C, Simonsen A, Sinclair DA, Singh R, Sinha D, Sinicrope FA, Sirko A, Siu PM, Sivridis E, Skop V, Skulachev VP, Slack RS, Smaili SS, Smith DR, Soengas MS, Soldati T, Song X, Sood AK, Soong TW, Sotgia F, Spector SA, Spies CD, Springer W, Srinivasula SM, Stefanis L, Steffan JS, Stendel R, Stenmark H, Stephanou A, Stern ST, Sternberg C, Stork B, Stralfors P, Subauste CS, Sui X, Sulzer D, Sun J, Sun SY, Sun ZJ, Sung JJ, Suzuki K, Suzuki T, Swanson MS, Swanton C, Sweeney ST, Sy LK, Szabadkai G, Tabas I, Taegtmeyer H, Tafani M, Takacs-Vellai K, Takano Y, Takegawa K, Takemura G, Takeshita F, Talbot NJ, Tan KS, Tanaka K, Tang D, Tanida I, Tannous BA, Tavernarakis N, Taylor GS, Taylor GA, Taylor JP, Terada LS, Terman A, Tettamanti G, Thevissen K, Thompson CB, Thorburn A, Thumm M, Tian F, Tian Y, Tocchini-Valentini G, Tolkovsky AM, Tomino Y, Tonges L, Tooze SA, Tournier C, Tower J, Towns R, Trajkovic V, Travassos LH, Tsai TF, Tschan MP, Tsubata T, Tsung A, Turk B, Turner LS, Tyagi SC, Uchiyama Y, Ueno T, Umekawa M, Umemiya-Shirafuji R, Unni VK, Vaccaro MI, Valente EM, Van den Berghe G, van der Klei IJ, van Doorn W, van Dyk LF, van Egmond M, van Grunsven LA, Vandenabeele P, Vandenberghe WP, Vanhorebeek I, Vaquero EC, Velasco G, Vellai T, Vicencio JM, Vierstra RD, Vila M, Vindis C, Viola G, Viscomi MT, Voitsekhovskaja OV, von Haefen C, Votruba M, Wada K, Wade-Martins R, Walker CL, Walsh CM, Walter J, Wan XB, Wang A, Wang C, Wang D, Wang F, Wang G, Wang H, Wang HG, Wang HD, Wang J, Wang K, Wang M, Wang RC, Wang X, Wang YJ, Wang Y, Wang Z, Wang ZC, Wansink DG, Ward DM, Watada H, Waters SL, Webster P, Wei L, Weihl CC, Weiss WA, Welford SM, Wen LP, Whitehouse CA, Whitton JL, Whitworth AJ, Wileman T, Wiley JW, Wilkinson S, Willbold D, Williams RL, Williamson PR, Wouters BG, Wu C, Wu DC, Wu WK, Wyttenbach A, Xavier RJ, Xi Z, Xia P, Xiao G, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, Youle RJ, Younes A, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zacarin E, Zacks D, Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ 3rd, Zeitlin SO, Zhang H, Zhang HL, Zhang J, Zhang JP, Zhang L, Zhang MY, Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, Zoladek T, Zong WX, Zorzano A, Zschocke J, Zuckerbraun B (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445–544

    Google Scholar 

  20. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101(6):1566–1571. https://doi.org/10.1073/pnas.0308319100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hartman J, Lindberg K, Inzunza J, Wan J, Strom A, Gustafsson J (2006) Estrogen receptor beta represses breast tumor growth and angiogenesis in vivo. J Clin Oncol 24(18):565s–565s

    Google Scholar 

  22. Vivar OI, Zhao X, Saunier EF, Griffin C, Mayba OS, Tagliaferri M, Cohen I, Speed TP, Leitman DC (2010) Estrogen receptor beta binds to and regulates three distinct classes of target genes. J Biol Chem 285(29):22059–22066. https://doi.org/10.1074/jbc.M110.114116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, Esteva FJ, Gustafsson JA (2012) ERbeta1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res 14(6):R148. https://doi.org/10.1186/bcr3358

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M, Clarke R (2007) Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J 21(14):4013–4027. https://doi.org/10.1096/fj.06-7990com

    Article  CAS  PubMed  Google Scholar 

  25. Picard N, Charbonneau C, Sanchez M, Licznar A, Busson M, Lazennec G, Tremblay A (2008) Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta. Mol Endocrinol 22(2):317–330. https://doi.org/10.1210/me.2007-0281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Thomas C, Gustafsson JA (2012) Targeting PES1 for restoring the ERalpha/ERbeta ratio in breast cancer. J Clin Invest 122(8):2771–2773. https://doi.org/10.1172/JCI65133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cheng L, Li J, Han Y, Lin J, Niu C, Zhou Z, Yuan B, Huang K, Jiang K, Zhang H, Ding L, Xu X, Ye Q (2012) PES1 promotes breast cancer by differentially regulating ERalpha and ERbeta. J Clin Invest 122(8):2857–2870. https://doi.org/10.1172/JCI62676

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Tremblay A, Tremblay GB, Labrie F, Giguere V (1999) Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3(4):513–519

    Article  CAS  PubMed  Google Scholar 

  29. Yuan B, Cheng L, Chiang HC, Xu X, Han Y, Su H, Wang L, Zhang B, Lin J, Li X, Xie X, Wang T, Tekmal RR, Curiel TJ, Yuan ZM, Elledge R, Hu Y, Ye Q, Li R (2014) A phosphotyrosine switch determines the antitumor activity of ERbeta. J Clin Invest 124(8):3378–3390. https://doi.org/10.1172/JCI74085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yuan B, Cheng L, Gupta K, Chiang HC, Gupta HB, Sareddy GR, Wang D, Lathrop K, Elledge R, Wang P, McHardy S, Vadlamudi R, Curiel TJ, Hu Y, Ye Q, Li R (2016) Tyrosine phosphorylation regulates ERbeta ubiquitination, protein turnover, and inhibition of breast cancer. Oncotarget 7(27):42585–42597. https://doi.org/10.18632/oncotarget.10018

    Article  PubMed  PubMed Central  Google Scholar 

  31. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537–2541

    CAS  PubMed  Google Scholar 

  32. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, Lansdown MR, Parkes AT, Hanby AM, Markham AF, Speirs V (2003) Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 201(2):213–220. https://doi.org/10.1002/path.1436

    Article  CAS  PubMed  Google Scholar 

  33. Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M, Gustafsson JA (2014) Differential expression of estrogen receptor alpha, beta1, and beta2 in lobular and ductal breast cancer. Proc Natl Acad Sci U S A 111(5):1933–1938. https://doi.org/10.1073/pnas.1323719111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC (2015) ERbeta expression and breast cancer risk prediction for women with atypias. Cancer Prev Res (Phila) 8(11):1084–1092. https://doi.org/10.1158/1940-6207.CAPR-15-0198

    Article  CAS  Google Scholar 

  35. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11(3):537–551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bado I, Nikolos F, Rajapaksa G, Wu W, Castaneda J, Krishnamurthy S, Webb P, Gustafsson JA, Thomas C (2017) Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. Breast Cancer Res 19(1):79. https://doi.org/10.1186/s13058-017-0872-z

    Article  PubMed  PubMed Central  Google Scholar 

  37. Swedenborg E, Power KA, Cai W, Pongratz I, Ruegg J (2009) Regulation of estrogen receptor beta activity and implications in health and disease. Cell Mol Life Sci 66(24):3873–3894. https://doi.org/10.1007/s00018-009-0118-z

    Article  CAS  PubMed  Google Scholar 

  38. Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, Kissler S, Gatje R, Karn T, Kaufmann M (2005) Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer 12(4):903–916. https://doi.org/10.1677/erc.1.01088

    Article  CAS  PubMed  Google Scholar 

  39. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA, Dahlman-Wright K (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22(48):7600–7606. https://doi.org/10.1038/sj.onc.1207100

    Article  CAS  PubMed  Google Scholar 

  40. Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S, Shaaban AM, Smith L, Speirs V (2010) Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. Cancer Res 70(11):4778–4784. https://doi.org/10.1158/0008-5472.CAN-09-4104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Tateishi Y, Kawabe Y, Chiba T, Murata S, Ichikawa K, Murayama A, Tanaka K, Baba T, Kato S, Yanagisawa J (2004) Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 23(24):4813–4823. https://doi.org/10.1038/sj.emboj.7600472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Pratt WB, Toft DO (1997) Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18(3):306–360. https://doi.org/10.1210/edrv.18.3.0303

    Article  CAS  PubMed  Google Scholar 

  43. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L (2001) Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7(7):2076–2084

    CAS  PubMed  Google Scholar 

  44. Tateishi Y, Sonoo R, Sekiya Y, Sunahara N, Kawano M, Wayama M, Hirota R, Kawabe Y, Murayama A, Kato S, Kimura K, Yanagisawa J (2006) Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis. Mol Cell Biol 26(21):7966–7976. https://doi.org/10.1128/MCB.00713-06

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Fan M, Park A, Nephew KP (2005) CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol 19(12):2901–2914. https://doi.org/10.1210/me.2005-0111

    Article  CAS  PubMed  Google Scholar 

  46. Alonso L, Gallego E, Gonzalez FJ, Sanchez-Munoz A, Torres E, Pajares BI, Leeflang S, Baha C (2009) Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study. Clin Transl Oncol 11(11):748–752

    Article  CAS  PubMed  Google Scholar 

  47. Ohshiro K, Kumar R (2015) MTA1 regulation of ERbeta pathway in salivary gland carcinoma cells. Biochem Biophys Res Commun 464(4):1016–1021. https://doi.org/10.1016/j.bbrc.2015.07.043

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Zhao Z, Wang L, James T, Jung Y, Kim I, Tan R, Hoffmann FM, Xu W (2015) Reciprocal regulation of ERalpha and ERbeta stability and activity by diptoindonesin G. Chem Biol 22(12):1608–1621. https://doi.org/10.1016/j.chembiol.2015.10.011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Sternlicht MD (2006) Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res 8(1):201. https://doi.org/10.1186/bcr1368

    Article  CAS  PubMed  Google Scholar 

  50. Korach KS, Couse JF, Curtis SW, Washburn TF, Lindzey J, Kimbro KS, Eddy EM, Migliaccio S, Snedeker SM, Lubahn DB, Schomberg DW, Smith EP (1996) Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Prog Horm Res 51:159–186 discussion 186–158

    CAS  PubMed  Google Scholar 

  51. Mallepell S, Krust A, Chambon P, Brisken C (2006) Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A 103(7):2196–2201. https://doi.org/10.1073/pnas.0510974103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ciarloni L, Mallepell S, Brisken C (2007) Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci U S A 104(13):5455–5460. https://doi.org/10.1073/pnas.0611647104

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner M, Gustafsson JA (2002) Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 99(24):15578–15583. https://doi.org/10.1073/pnas.192561299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Antal MC, Krust A, Chambon P, Mark M (2008) Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci U S A 105(7):2433–2438. https://doi.org/10.1073/pnas.0712029105

    Article  PubMed  PubMed Central  Google Scholar 

  55. Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA (2005) Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24(44):6605–6616. https://doi.org/10.1038/sj.onc.1208807

    Article  CAS  PubMed  Google Scholar 

  56. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433. https://doi.org/10.1677/JOE-07-0087

    Article  CAS  PubMed  Google Scholar 

  57. Treeck O, Lattrich C, Springwald A, Ortmann O (2010) Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 120(3):557–565. https://doi.org/10.1007/s10549-009-0413-2

    Article  CAS  PubMed  Google Scholar 

  58. Cotrim CZ, Fabris V, Doria ML, Lindberg K, Gustafsson JA, Amado F, Lanari C, Helguero LA (2013) Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 32(19):2390–2402. https://doi.org/10.1038/onc.2012.261

    Article  CAS  PubMed  Google Scholar 

  59. Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Strom A, Gustafsson JA, Rietjens I, Murk AJ (2008) Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci 105(2):303–311. https://doi.org/10.1093/toxsci/kfn141

    Article  CAS  PubMed  Google Scholar 

  60. Wiesen JF, Young P, Werb Z, Cunha GR (1999) Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. Development 126(2):335–344

    CAS  PubMed  Google Scholar 

  61. Samanta S, Sharma VM, Khan A, Mercurio AM (2012) Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene 31:4689. https://doi.org/10.1038/onc.2011.620

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Song W, Tang L, Xu Y, Sun Q, Yang F, Guan X (2017) ERbeta1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1. J Exp Clin Cancer Res 36(1):75. https://doi.org/10.1186/s13046-017-0545-x

    Article  PubMed  PubMed Central  Google Scholar 

  63. Schuler-Toprak S, Haring J, Inwald EC, Moehle C, Ortmann O, Treeck O (2016) Agonists and knockdown of estrogen receptor beta differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer 16(1):951. https://doi.org/10.1186/s12885-016-2973-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Hinsche O, Girgert R, Emons G, Grundker C (2015) Estrogen receptor beta selective agonists reduce invasiveness of triple-negative breast cancer cells. Int J Oncol 46(2):878–884. https://doi.org/10.3892/ijo.2014.2778

    Article  CAS  PubMed  Google Scholar 

  65. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R (1998) Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 58(2):210–214

    CAS  PubMed  Google Scholar 

  66. Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A (2005) Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin Cancer Res 11(20):7579–7585. https://doi.org/10.1158/1078-0432.CCR-05-0728

    Article  CAS  PubMed  Google Scholar 

  67. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011–5020. https://doi.org/10.1038/sj.onc.1206787

    Article  CAS  PubMed  Google Scholar 

  68. Rajapaksa G, Nikolos F, Bado I, Clarke R, Gustafsson JA, Thomas C (2015) ERbeta decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. Oncogene 34(31):4130–4141. https://doi.org/10.1038/onc.2014.343

    Article  CAS  PubMed  Google Scholar 

  69. Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC (2007) Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J Cell Biochem 101(5):1125–1147. https://doi.org/10.1002/jcb.21205

    Article  CAS  PubMed  Google Scholar 

  70. Bialesova L, Xu L, Gustafsson JA, Haldosen LA, Zhao C, Dahlman-Wright K (2017) Estrogen receptor beta2 induces proliferation and invasiveness of triple negative breast cancer cells: association with regulation of PHD3 and HIF-1alpha. Oncotarget 8(44):76622–76633. https://doi.org/10.18632/oncotarget.20635

    Article  PubMed  PubMed Central  Google Scholar 

  71. Faria M, Karami S, Granados-Principal S, Dey P, Verma A, Choi DS, Elemento O, Bawa-Khalfe T, Chang JC, Strom AM, Gustafsson JA (2018) The ERbeta4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERbeta variants ERbeta2 and ERbeta5 increase aggressiveness of TNBC by regulation of hypoxic signaling. Oncotarget 9(15):12201–12211. https://doi.org/10.18632/oncotarget.24134

    Article  PubMed  PubMed Central  Google Scholar 

  72. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14(16):5228–5235. https://doi.org/10.1158/1078-0432.CCR-07-4528

    Article  CAS  PubMed  Google Scholar 

  73. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA (2002) Estrogen receptor beta in breast cancer. Endocr Relat Cancer 9(1):1–13

    Article  CAS  PubMed  Google Scholar 

  74. Haldosen LA, Zhao C, Dahlman-Wright K (2014) Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 382(1):665–672. https://doi.org/10.1016/j.mce.2013.08.005

    Article  CAS  PubMed  Google Scholar 

  75. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66(23):11207–11213. https://doi.org/10.1158/0008-5472.CAN-06-0017

    Article  CAS  PubMed  Google Scholar 

  76. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64(1):423–428

    Article  CAS  PubMed  Google Scholar 

  77. Shanle EK, Zhao Z, Hawse J, Wisinski K, Keles S, Yuan M, Xu W (2013) Research resource: global identification of estrogen receptor beta target genes in triple negative breast cancer cells. Mol Endocrinol 27(10):1762–1775. https://doi.org/10.1210/me.2013-1164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F (2001) ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142(9):4120–4130. https://doi.org/10.1210/endo.142.9.8395

    Article  CAS  PubMed  Google Scholar 

  79. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL (2011) FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471(7339):523–526. https://doi.org/10.1038/nature09870

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Lu W, Katzenellenbogen BS (2017) Estrogen receptor-beta modulation of the ERalpha-p53 loop regulating gene expression, proliferation, and apoptosis in breast cancer. Horm Cancer 8(4):230–242. https://doi.org/10.1007/s12672-017-0298-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Reese JM, Bruinsma ES, Monroe DG, Negron V, Suman VJ, Ingle JN, Goetz MP, Hawse JR (2017) ERbeta inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer. Oncotarget 8(57):96506–96521. https://doi.org/10.18632/oncotarget.21787

    Article  PubMed  PubMed Central  Google Scholar 

  82. Park C, Lee Y (2014) Overexpression of ERbeta is sufficient to inhibit hypoxia-inducible factor-1 transactivation. Biochem Biophys Res Commun 450(1):261–266. https://doi.org/10.1016/j.bbrc.2014.05.107

    Article  CAS  PubMed  Google Scholar 

  83. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M, Shiu R (2005) Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 34(2):553–566. https://doi.org/10.1677/jme.1.01688

    Article  CAS  PubMed  Google Scholar 

  84. Bado I, Pham E, Soibam B, Nikolos F, Gustafsson J-Å, Thomas C (2018) ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. Oncotarget 9(32):22509–22522. https://www.ncbi.nlm.nih.gov/pubmed/29854295

  85. Lindberg K, Helguero LA, Omoto Y, Gustafsson JA, Haldosen LA (2011) Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res 13(2):R43. https://doi.org/10.1186/bcr2865

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Thomas CG, Strom A, Lindberg K, Gustafsson JA (2011) Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling. Breast Cancer Res Treat 127(2):417–427. https://doi.org/10.1007/s10549-010-1011-z

    Article  CAS  PubMed  Google Scholar 

  87. Rajapaksa G, Thomas C, Gustafsson JA (2016) Estrogen signaling and unfolded protein response in breast cancer. J Steroid Biochem Mol Biol 163:45. https://doi.org/10.1016/j.jsbmb.2016.03.036

    Article  CAS  PubMed  Google Scholar 

  88. Sanchez M, Picard N, Sauve K, Tremblay A (2013) Coordinate regulation of estrogen receptor beta degradation by Mdm2 and CREB-binding protein in response to growth signals. Oncogene 32(1):117–126. https://doi.org/10.1038/onc.2012.19

    Article  CAS  PubMed  Google Scholar 

  89. Jonsson P, Katchy A, Williams C (2014) Support of a bi-faceted role of estrogen receptor beta (ERbeta) in ERalpha-positive breast cancer cells. Endocr Relat Cancer 21(2):143–160. https://doi.org/10.1530/ERC-13-0444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Ma R, Karthik GM, Lovrot J, Haglund F, Rosin G, Katchy A, Zhang X, Viberg L, Frisell J, Williams C, Linder S, Fredriksson I, Hartman J (2017) Estrogen receptor beta as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst 109(3):1–14. https://doi.org/10.1093/jnci/djw236

    Article  PubMed  Google Scholar 

  91. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247(1):75–78. https://doi.org/10.1006/bbrc.1998.8738

    Article  CAS  PubMed  Google Scholar 

  92. Green CA, Peter MB, Speirs V, Shaaban AM (2008) The potential role of ER beta isoforms in the clinical management of breast cancer. Histopathology 53(4):374–380. https://doi.org/10.1111/j.1365-2559.2008.02968.x

    Article  CAS  PubMed  Google Scholar 

  93. Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, Lam EW, Cheng G, Gustafsson JA, Dahlman-Wright K (2007) Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 67(8):3955–3962. https://doi.org/10.1158/0008-5472.CAN-06-3505

    Article  CAS  PubMed  Google Scholar 

  94. Helguero LA, Lindberg K, Gardmo C, Schwend T, Gustafsson JA, Haldosen LA (2008) Different roles of estrogen receptors alpha and beta in the regulation of E-cadherin protein levels in a mouse mammary epithelial cell line. Cancer Res 68(21):8695–8704. https://doi.org/10.1158/0008-5472.CAN-08-0788

    Article  CAS  PubMed  Google Scholar 

  95. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Network TR, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519. https://doi.org/10.1016/j.cell.2015.09.033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Bado I, Nikolos F, Rajapaksa G, Gustafsson JA, Thomas C (2016) ERbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Oncotarget 7(12):13599–13611. https://doi.org/10.18632/oncotarget.7300

    Article  PubMed  PubMed Central  Google Scholar 

  97. Lindberg K, Strom A, Lock JG, Gustafsson JA, Haldosen LA, Helguero LA (2010) Expression of estrogen receptor beta increases integrin alpha 1 and integrin beta 1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 222(1):156–167. https://doi.org/10.1002/Jcp.21932

    Article  CAS  PubMed  Google Scholar 

  98. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM (2004) Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164(6):2003–2012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Hankinson SE, Colditz GA, Willett WC (2004) Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6(5):213–218. https://doi.org/10.1186/bcr921

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168

    CAS  PubMed  Google Scholar 

  101. Speirs V, Green AR, Hughes TA, Ellis IO, Saunders PT, Shaaban AM (2008) Clinical importance of estrogen receptor beta isoforms in breast cancer. J Clin Oncol 26(35):5825.; author reply 5825–5826. https://doi.org/10.1200/JCO.2008.19.5909

    Article  PubMed  Google Scholar 

  102. Andersson S, Sundberg M, Pristovsek N, Ibrahim A, Jonsson P, Katona B, Clausson CM, Zieba A, Ramstrom M, Soderberg O, Williams C, Asplund A (2017) Insufficient antibody validation challenges oestrogen receptor beta research. Nat Commun 8:15840. https://doi.org/10.1038/ncomms15840

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Nikolos F, Thomas C, Rajapaksa G, Bado I, Gustafsson JA (2014) ERbeta regulates NSCLC phenotypes by controlling oncogenic RAS signaling. Mol Cancer Res 12:843. https://doi.org/10.1158/1541-7786.MCR-13-0663

    Article  CAS  PubMed  Google Scholar 

  104. Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR (2014) ERbeta1: characterization, prognosis, and evaluation of treatment strategies in ERalpha-positive and -negative breast cancer. BMC Cancer 14:749. https://doi.org/10.1186/1471-2407-14-749

    Article  PubMed  PubMed Central  Google Scholar 

  105. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57(5):523–528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Marotti JD, Collins LC, Hu R, Tamimi RM (2010) Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 23(2):197–204. https://doi.org/10.1038/modpathol.2009.158

    Article  CAS  PubMed  Google Scholar 

  107. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26(22):3727–3734. https://doi.org/10.1200/JCO.2007.14.2968

    Article  PubMed  Google Scholar 

  108. Yan M, Rayoo M, Takano EA, Fox SB (2011) Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat 126(2):395–405. https://doi.org/10.1007/s10549-010-0941-9

    Article  CAS  PubMed  Google Scholar 

  109. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H (2007) Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 37(11):820–828. https://doi.org/10.1093/jjco/hym114

    Article  PubMed  Google Scholar 

  110. Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y, Akiyama F (2015) Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. Breast Cancer 22(1):71–78. https://doi.org/10.1007/s12282-013-0455-5

    Article  PubMed  Google Scholar 

  111. O’Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, Foster CS (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694–1702. https://doi.org/10.1038/sj.bjc.6602183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Elebro K, Borgquist S, Rosendahl AH, Markkula A, Simonsson M, Jirstrom K, Rose C, Ingvar C, Jernstrom H (2017) High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients-results from a population-based breast cancer cohort. Clin Cancer Res 23(3):766–777. https://doi.org/10.1158/1078-0432.CCR-16-1095

    Article  CAS  PubMed  Google Scholar 

  113. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nistico C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 10(5):R74. https://doi.org/10.1186/bcr2139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X (2015) ERbeta1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat 152(2):255–269. https://doi.org/10.1007/s10549-015-3467-3

    Article  CAS  PubMed  Google Scholar 

  115. Tan W, Li Q, Chen K, Su F, Song E, Gong C (2016) Estrogen receptor beta as a prognostic factor in breast cancer patients: a systematic review and meta-analysis. Oncotarget 7(9):10373–10385. https://doi.org/10.18632/oncotarget.7219

    Article  PubMed  PubMed Central  Google Scholar 

  116. Liu J, Guo H, Mao K, Zhang K, Deng H, Liu Q (2016) Impact of estrogen receptor-beta expression on breast cancer prognosis: a meta-analysis. Breast Cancer Res Treat 156(1):149–162. https://doi.org/10.1007/s10549-016-3721-3

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX, USA

    Christoforos Thomas & Jan-Åke Gustafsson

Authors
  1. Christoforos Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan-Åke Gustafsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cancer Biology, Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Xiaoting Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thomas, C., Gustafsson, JÅ. (2019). Estrogen Receptor β and Breast Cancer. In: Zhang, X. (eds) Estrogen Receptor and Breast Cancer. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-99350-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-99350-8_12

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-99349-2

  • Online ISBN: 978-3-319-99350-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation